66th ASH Annual Meeting: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies

Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities Oral and Poster Abstracts
Oral

Research, Clinical trials, Lymphoid Leukemias, ALL, Hodgkin lymphoma, Adult, Acute Myeloid Malignancies, AML, MDS, Lymphomas, Clinical Practice (Health Services and Quality), Elderly, Translational Research, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Young adult , Myeloid Malignancies, Miscellaneous Cellular Therapies, Study Population, Human, Measurable Residual Disease , Transplantation (Allogeneic and Autologous)

Hall B (San Diego Convention Center)

Moderators:

Lekha Mikkilineni, MD, MA, and Natalie Grover, MD, NULL

Disclosures:

Grover: Seagen: Honoraria; Novartis: Honoraria; Regeneron: Honoraria, Research Funding; ADC Therapeutics: Honoraria; BMS: Honoraria, Research Funding; Caribou: Honoraria; Ono Pharma: Honoraria; Genentech: Honoraria; Cabaletta: Research Funding; Janssen: Honoraria; Kite: Honoraria; Sangamo: Current holder of stock options in a privately-held company; Poseida: Research Funding.

2:45 PM

919

CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma

Natalie Grover, MD¹, Dominic Moore²^*, Anastasia Ivanova, PhD²^*, Anne W Beaven, MD², Christopher Dittus, DO², Catherine Joyce Arago Cheng, BS²^*, Kelly Hoye²^*, Caroline Babinec²^*, Faith Brianne Buchanan, PA-C²^*, Angela Denise Spruill, ANP²^*, Ashley Zanter, ANP-BC, AOCNP²^*, John West, PhD²^*, J. Kaitlin Morrison, PhD²^*, Paul Armistead, MD, PhD²^*, Kimberly A. Kasow, DO²^*, Jonathan Serody, MD², Gianpietro Dotti, MD²^* and Barbara Savoldo, MD, PhD²^*

¹University of North Carolina, Chapel Hill, NC
²Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

3:00 PM

920

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30⁺ T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Ana Carolina Caballero Gonzalez, MD¹^*, Laura Escribà-Garcia, PhD²^*, Cristina Ujaldón-Miró, PhD²^*, Paula Pujol Fernández²^*, Rosanna Montserrat-Torres²^*, Eva Escudero-López²^*, Irene García-Cadenas, MD¹^*, Albert Esquirol, MD³^*, Maria Guardiola-Perello²^*, Paola Jara-Bustamante²^*, Rodrigo Martino, MD³^*, Jorge Sierra, MD³, Carmen Alvarez-Fernández, PhD²^* and Javier Briones¹^*

¹Hematology Service, Hospital Santa Creu i Sant Pau, Barcelona, Spain
²Institut Recerca Hospital de la Santa Creu i Sant Pau, Laboratory of Experimental Hematology-IIB, Barcelona, Spain
³Hematology and Hemotherapy Department, Hospital de la Sant Creu i Sant Pau. IIB-Sant Pau and José Carreras Leukemia Research Institutes. Universitat Autónoma de Barcelona, Barcelona, Spain

3:15 PM

921

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, MD, PhD^1,2,3^*, Yali Zhou, PhD⁴^*, Mingming Zhang^1,5,6^*, Shan Fu^2,5^*, Yong Yu⁴^*, Ming Gao⁴^*, Ruimin Hong^2,5,7^*, Houli Zhao⁷^*, Lu Han⁴^*, Jiangtao Ren, PhD⁴^* and He Huang, MD^1,2,8,9^*

¹Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
²Institute of Hematology, Zhejiang University, Hangzhou, China
³Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
⁴Nanjing Bioheng Biotech Co., Ltd., Nanjing, China
⁵Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
⁶The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangz, China
⁷Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
⁸Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁹Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University, Hangzhou, China

3:30 PM

922

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Susan Bal, MD¹^*, Larry D Anderson Jr., MD, PhD², Omar Nadeem, MD³, Jesús G. Berdeja, MD⁴, Adriana Rossi, MD, MSc⁵, Tara Gregory, MD⁶, Mehmet Hakan Koçoğlu, MD⁷^*, Thomas G. Martin, MD⁸, Daniel N. Egan, MD⁹, Luciano J. Costa, MD, PhD¹⁰, Hongxiang Hu, PhD¹¹^*, Jinjie Chen, PhD¹¹^*, Chaoqun Mei, PhD¹¹^*, Naomey Sarkis, PharmD, RPh¹¹^*, Alok Shrestha, MSc¹¹^*, Safiyyah Ziyad, PhD¹¹^*, Wei-Ming Kao, MD, PhD¹¹^*, Allison J Kaeding, MD¹¹^*, Michael R. Burgess, MD, PhD¹¹ and Myo Htut, MD¹²

¹University of Alabama at Birmingham, Birmingham, AL
²Myeloma, Waldenstrom’s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
³Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
⁴Sarah Cannon Cancer Center at Tennessee Oncology, Nashville, TN
⁵Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁶Sarah Cannon Cancer Network, Colorado Blood Cancer Institute, Denver, CO
⁷University of Maryland, Greenebaum Comprehensive Cancer, Baltimore, MD
⁸Department of Hematology, University of California at San Francisco, San Francisco, CA
⁹Swedish Cancer Institute, Seattle, WA
¹⁰Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Vestavia, AL
¹¹Bristol Myers Squibb, Princeton, NJ
¹²Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA

3:45 PM

923

A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

Hua Jiang, PhD¹^*, Lu Li¹^*, Kaili Chen, MD¹^*, Chunchen Yang, MD¹^*, Ruixue Ma¹^*, Liangyu Xie, MD¹^*, Can He, MD¹^*, Fang Feng¹^*, Hao Wu¹^*, Xiaomei Chen¹^*, Dan Li²^*, Xianghai Cai²^*, Jin Zhao³^*, Tao Guan, PhD⁴^*, Li Ma³^*, Min Bai, PhD³^*, Guoxiang Wu²^*, Liping Su³ and Weijun Fu¹^*

¹Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
²Novatim Immune Therapeutics (Zhejiang) Co., Ltd., Shanghai, China
³Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Taiyuan, China
⁴Department of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, AL, China

4:00 PM

924

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Monzr M. Al Malki, MD¹, Alla Keyzner, MD², Uday Popat, MD³, Yi-Bin Chen, MD, MS⁴, Hyung C Suh, MD, PhD⁵, Tania Jain, MD⁶, Melhem M. Solh, MD⁷, Anson Snow, MD⁸, Saar Gill, MD, PhD⁹, Lohith Gowda, MD¹⁰^*, Joseph Uberti, MD, PhD¹¹, Erica Buonomo, PhD¹²^*, Yun Wang, PhD¹²^*, Nancy Nabilsi, PhD¹²^*, Timothy White¹²^*, Cuong Nguyen¹³^*, Jim Murray¹²^*, Gavin MacBeath, PhD¹²^*, Chrystal Louis, MD, MPH¹², Shrikanta Chattopadhyay, MD¹², Michelle Matzko, MD, PhD¹⁴^* and Ran Reshef, MD, MSc¹⁵

¹Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
²Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA
⁵Stem Cell Transplantation and Cellular Therapy Program, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
⁶Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁷Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA
⁸Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
⁹University of Pennsylvania, Philadelphia, PA
¹⁰Yale Cancer Center and Yale School of Medicine, New Haven, CT
¹¹Karmanos Cancer Institute, Detroit, MI
¹²TScan Therapeutics, Waltham, MA
¹³Biostatistical Consulting, Lexington
¹⁴TScanTherapeutics, Waltham, MA
¹⁵Division of Hematology & Oncology, Columbia University Medical Center, New York

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.O2.6 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies